Ameresco, Inc. (AMRC)
NYSEIndustrialsEngineering & ConstructionSnapshot 2026-07-23
Reading AMRC? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →NYSEIndustrialsEngineering & ConstructionSnapshot 2026-07-23
Reading AMRC? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company has shown strong recent financial performance, but its management execution has been volatile, leading to uncertainty in its long-term trajectory.
The current valuation is considered expensive compared to peers, with an expectations gap indicating that the market is pricing in some fragility. The stock's recent valuation increase suggests that investors are aware of the risks but still see potential.
Management has set ambitious targets for revenue growth and earnings, but recent results show mixed progress. The near-term risk of missing earnings estimates remains, as the company has a history of earnings misses.
The thesis hinges on the performance of sector bellwethers and AMRC's ability to meet its guidance. Positive momentum in the Industrials sector could support AMRC, while any downward revisions in guidance could negatively impact sentiment.
Over the next 1 to 3 years, AMRC's performance will depend on its execution and sector conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The earnings report will provide insights into financial health and progress towards goals.
Confirms one read:The earnings report shows a return to profit with positive net income.
Confirms the other:The earnings report shows ongoing losses or negative trends.
Why it matters: Updates on partnerships can signal growth opportunities and market expansion. They are key for future revenue.
Confirms:New partnerships or progress on current ones may be announced.
Disproves:No updates or bad news about partnerships.
Why it matters: Hitting or beating EPS guidance is key for investor trust. It shows progress to make money.
Confirms:Q2 non-GAAP EPS reported between $1.06 and $1.28.
Disproves:Q2 non-GAAP EPS was below $1.06. This shows ongoing problems.
Why it matters: Meeting the capex guidance of $300M to $350M is crucial for future growth. Deviations may signal financial strain.
Confirms:Capex reported in line with the $300M to $350M guidance during the next earnings report.
Disproves:Capex is reported well under $300M. This shows possible funding issues.
Why it matters: Improved revenue growth is key to reaching the $2.1 billion target for 2026. A strong Q2 would indicate better performance after a decline in Q1.
Confirms:Q2 revenue growth exceeds $500 million, showing a positive trend.
Disproves:Q2 revenue growth is still under $400 million. This shows ongoing struggles.
Why it matters: Keeping EPS guidance shows confidence in future profits. A miss would raise worries about finances.
Confirms:Management confirms non-GAAP EPS guidance of $1.06 to $1.28 during the next earnings call.
Disproves:Management cuts EPS guidance to below $1.06. This shows deeper problems.
Why it matters: Capex levels will show if Ameresco is spending enough for growth.
Confirms:Capex for 2026 is $300 million or more. This supports growth plans.
Disproves:Capex is below $250 million. This shows possible underinvestment in growth.
Why it matters: Non-GAAP EPS helps us see how much profit Ameresco makes and its financial health.
Confirms:Non-GAAP EPS reported at or above $0.18 for Q2 2026, indicating progress.
Disproves:Non-GAAP EPS is below $0.15 for Q2 2026. This shows profit challenges.